Archive | Redefining Early Stage Investments RSS feed for this section

Timing and Relationship: The Key to Compelling Investor Mandates

8 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

As the life science arena shifts, so do investment and licensing mandates and the technologies that investors and strategic partners seek. Life Science Nation (LSN) is known for its curated partnering database for fundraising early-stage companies across the silos of drugs, devices, diagnostics and digital health. This database has ten categories of investors ranging from angel groups and family offices to VCs, PEs, Big Pharma/Medtech, foundations and the non-dilutive federal, state and regional agencies.

The LSN mantra to healthcare scientist-entrepreneurs and fundraising CEOs is that partnering is a numbers game, and that getting a Global Target List (GTL) of potential partners that are a fit for your stage of development and product set is a crucial step to a successful fundraising campaign. Furthermore, it’s essential to canvass outside your region, engaging global partners to maximize the likelihood of building a relationship that could secure a partnership. 

The LSN Investor Research Team curates the LSN Investor Database, which consists of profiles that fundraising clients can access with an annual subscription. Tools like the database are essential aids for success in a global fundraising campaign. The database features more than ten thousand investor contacts representing several thousand funding and licensing firms. The team’s goal is to keep all the partnering mandates updated in order to ensure the best fit, and this is done through bi-annual interviews. 

These firms are willing to be part of the LSN Investor Platform because we provide them with quality deal-flow, companies that know they are a fit for the firm’s investment theme or partnering interests. Additionally, each year, five Redefining Ealy Stage Investments (RESI) partnering events attract the who’s-who of early-stage life science investing and give them another avenue to connect with fundraising companies that match their interests. These conferences consist of investor panels, workshops, and matched partnering meetings, taking advantage of the profiles the investor research team gathers and the long-term relationships we build while keeping their mandates current.  

The relationship between LSN and the global investor community is deep and has helped hundreds of companies get funded by connecting with investors and partners. Just this week, the Investor Research Team has updated over forty-five mandates, facilitating super fresh profile updates for LSN clients seeking funding. Check out this week’s investor mandates and reach out to your LSN business development representative to view these investors and learn how to get plugged into the LSN partnering ecosystem.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada 
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Ashley Zborowski
Director of Business Development
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!

Starting with Pep: An Early-Stage Conversation with Creative Bio-Peptides

8 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Creative Bio-Peptides is an early-stage company, founded and led by Dr. Michael Ruff, with a mission to improve lives through developing oral receptor-active peptides targeting neurodegenerative diseases. We spoke with Chief Business Officer, Michael Simon about the early-stage journey of Creative Bio-Peptides – how it was started, what their strategy looks like today, and where they see the company going forward.

Creative Bio-Peptides is a past participant at an Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by April 9 to save $100 on super early bird rates.

Digital RESI June Super Early Bird Ends Tomorrow

8 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Digital Redefining Early Stage Investments (RESI), June 8-10, is around the corner, which means that super early bird rates end tomorrow! Sign up by Friday, April 9 to save $100 on registration to take advantage of the RESI partnering system which enables early-stage fundraising executives to source investors and strategic partners based on a fit for their product and stage of development.

Digital RESI June also offers a variety of investor panels, educational workshops, and the Innovator’s Pitch Challenge – all designed to offer valuable insight to entrepreneurs and opportunities to make matches, build relationships, and cut deals. Digital RESI has been a part of hundreds of companies’ early-stage fundraising success stories. Sign up to save and make it a part of yours!

Innovator’s Pitch Challenge: Now Accepting Applications!

1 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI June is fast approaching, and is now accepting applications to the Innovator’s Pitch Challenge (IPC)! The sessions take place virtually June 8-10. IPC applications are now open until Friday, May 14.

The IPC is a virtual pitch experience in which participating companies receive a dedicated webpage accessible via the event live agenda, as well as the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services.

ARJUNA Therapeutics CEO, Ross Breckenridge said of the March Innovator’s Pitch Challenge:

I’m really happy to have participated in RESI and the IPC format. The investors were predominantly stage-and sector-appropriate for a biotech start up (not always the case in meetings like this). The IPC format was helpful in that we were able to post a short pitch online for on-demand viewing as well as having a ‘live’ discussion. Several of the panelists met with me after the panel, and I’ve been contacted by one investor (so far) outside the meeting after they’d seen the video pitch. I’m happy to recommend this meeting and the IPC format for early-stage biotech companies-I think this was money and time well spent for us.

Selected companies pay their registration, as well as an additional pitching fee, so apply before April 9 to save on super early bird rates! BrainXell CEO, Shouming Du also said of his experience in March:

I have had a very positive experience at RESI, my first time. Workshop, panel discussion, and IPC are complementary to each other. I like IPC format, posting materials in advance and focusing on live discussion in 10 minutes. I feel the extra money I spent on IPC is worth it, not just exposure or those 10 min Q&A. It has forced me to prepare relevant materials.

Thrive Bioscience CEO, Co-Founder & Board Director, Thomas Forest Farb-Horch won Digital RESI March’s IPC, and reached out to the RESI team to share his experience:

The quality of the judges and questions in the four Pitch Challenges were phenomenal. Panels were phenomenal, and I really enjoyed being on the Tools panel. Tad Weems and the other panelists did a fantastic job…My companies received lots of good leads and have lots of work to do, still following up.

Check out Thrive Bioscience’s sample dedicated webpage and apply for the Digital RESI June IPC by May 14!

Digital RESI June – Agenda Announced!

25 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

It has been over a year since Life Science Nation (LSN) started organizing virtual conferences, which has been met with overwhelming support from the community of investors, service providers, and early-stage companies within life science and healthcare. Thank you to all who have supported LSN throughout the past year!

LSN is pleased to announce the newest, 3-day Digital RESI conference, June 8-10. Check out the agenda below!

Digital RESI June Agenda

 Tuesday
June 8
Wednesday
June 9
Thursday
June 10
10:00amCorporate Venture Capital
The Corporate Landscape Morphed & New Opportunities Abound
Angel Investors
Explaining the Process of Engagement
Medtech Strategics
Large Medical Device Firms Seeking External Innovation
12:00pmInnovator’s Pitch Session #1Innovator’s Pitch Session #3Innovator’s Pitch Session #5
2:00pmImpact Investors
Life Science Investors Looking for More Than Financial Returns
Family Offices
How Do Family Offices View Seed & Series A Rounds?
Big Pharma
Pipeline Strategy for Preclinical and Early Clinical Assets
3:00pmInnovator’s Pitch Session #2Innovator’s Pitch Session #4Innovator’s Pitch Session #6

Each panel is held live during the conference and will feature active investors and strategic partners as participants sharing their insights and offering helpful tips to fundraising executives.

Digital RESI June will also feature the Innovator’s Pitch Challenge (IPC) – the virtual pitch experience in which participating companies receive a dedicated webpage accessible via the event live agenda, as well as the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services. These sessions provide valuable insights and feedback to help companies improve their skills, as well as build connections in a valuable setting.

IPC applications are now open until Friday, May 14. Selected companies pay their registration, as well as an additional pitching fee, so apply before April 9 to save on super early bird rates!

Congratulations to the 4D Meets AI Innovator’s Pitch Challenge Winners!

25 Mar

By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN)’s 4D Meets AI partnering conference successfully concluded last Friday, March 19. Over the two-day event, LSN featured seven exceptional startup companies at the intersection of AI and life science through the Innovator’s Pitch Challenge (IPC).

Each company was featured on a dedicated landing page that hosted their pitch video and supplementary materials, and they participated in a live Q&A session with a panel of investor pitch judges. Conference attendees were able to visit these landing pages or join the live Q&A sessions, and they were encouraged to vote for their favorite IPC companies before the end of the conference.

Many thanks to all the IPC companies for their hard work promoting their technologies and to the pitch judges who supported each session with their feedback. Each company was judged on their supporting materials, as well as their live pitch and Q&A. Congratulations to Huma.AI and Thrive Bioscience for winning their sessions!

Huma.ai is a venture-backed healthcare AI company. It’s ML-enabled, questions and answers-driven knowledge automation platform turns domain experts into their own data scientists so that they can make real-time decisions driven by data. According to its customers, Huma.ai has cracked the Holy Grail.

Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive has recently started selling the first two instruments in the family, the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, provides guidance and builds a significant database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells on an ongoing basis, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, as well as large and small pharma/biotech companies.

If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the Digital RESI IPC taking place June 8-10. Applications close May 14!

This image has an empty alt attribute; its file name is digital-june-2021-banner-1100.png

Congratulations to the LHI Innovator’s Pitch Challenge Winners!

25 Mar

By Jessica Yang, Senior Research Analyst, Asia Business Development, LSN

Life Science Nation (LSN)’s 2-day Longevity, Health & Innovation (LHI) digital partnering conference took place March 18-19. We are very excited to announce the Top Winners of each Innovator’s Pitch Challenge (IPC) session. As the popularity grows for LHI IPC, we had three sessions featuring Therapeutics, Medical Devices & Diagnostics, and Digital Health companies. Attendees voted for their favorite companies based on materials available on the companies’ dedicated webpages, as well as their live pitch and Q&A.

Thank you to each IPC company for participating and sharing your technology and story with the LHI community. Congratulations to the winners, and thanks to all for voting!

Session 1 (Therapeutics) Tied Winners

APIE-Therapeutics, Inc is a preclinical stage biopharmaceutical company pioneering the endothelium vascular niche repair and regeneration platform. By harnessing activation of the Apelin-APJ receptor, we intend to improve patients’ lives suffering from chronic diseases such as Idiopathic Pulmonary Fibrosis (IPF), KidneyMembranous Glomerulonephritis (MGN) & Chronic Kidney Disease (CKD), Scleroderma (SSc) and others.

Panaceutics Rx uses its patented technologies to enable easy access to affordable personalized medicine and wellness, offering unique combination forms to improve adherence, delivered direct to patients. Our mission is to enable personalized combination products for prevention and chronic therapy, with aids to formulation based on an individual’s digital health profile. Individualized, optimized combinations are enabled to be made on-demand using our robotic platforms and patented processes. Under 503A regulatory rules, Panaceutics automates the compounding of individualized therapies to match physician’s prescriptions. We deliver individualized combination therapies in consumer-friendly forms that promote adherence.

Session 2 (Digital Health) Winner

LifeBio is an age-tech company that captures individuals’ life stories and increases social connectedness— to enhance mental health and to improve Alzheimer’s care.

Session 3 (Medical Devices & Diagnostics) Winner

Eye movements offer a window into brain health. neuroFit licensed a NASA-developed oculometric technology co-invented by one of our founders that delivers eye-movement-based metrics, some well-known from physiology (e.g., latency, acceleration, gain) and other more modern sensorimotor metrics (e.g., direction noise, speed tuning) distilled into a summary metric, nFit. Compared to biomarkers from imaging and EEG, oculometric approaches require only a visual display and a well-designed tracking system to yield noninvasive, low-cost biomarkers that can be scaled on consumer devices.

If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the Digital RESI IPC taking place June 8-10. Applications close May 14!

This image has an empty alt attribute; its file name is digital-june-2021-banner-1100.png
%d bloggers like this: